Amicus Therapeutics Stock Price - FOLD

8.86
0.00 (0.0%)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Amicus Therapeutics Inc FOLD NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 8.86 0.00 0.00 0.00 8.86 04:00:00
Bid Price Ask Price Spread Spread % News
8.29 9.90 1.61 16.26% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 8.86 USD

Amicus Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.28B 257.24M $ -349.00M -1.51 - 253.83M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Amicus Therapeutics News

Loading Messages....

Latest FOLD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical FOLD Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week9.9010.848.639.243,135,894-1.04-10.51%
1 Month9.5310.846.258.633,945,765-0.67-7.03%
3 Months9.8011.296.259.353,207,244-0.94-9.59%
6 Months7.9011.296.259.193,109,3390.9612.15%
1 Year13.5114.726.2510.212,829,241-4.65-34.42%
3 Years7.1717.626.2511.962,735,2161.6923.57%
5 Years10.9518.834.4110.602,620,904-2.09-19.09%

Amicus Therapeutics Description

Amicus Therapeutics Inc is a biotechnology company. It is engaged in the discovery, development, and commercialization of medicines for various rare metabolic diseases. The firm offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 1/2 (ATB200-02) and Phase 3 (ATB200-03) clinical studies for an investigational enzyme replacement therapy (AT-GAA) for Pompe disease. Amicus Therapeutics has a strategic manufacturing collaboration with Thermo Fisher Scientific for conducting preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other Batten disease programs.


Your Recent History
NASDAQ
FOLD
Amicus The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.